krull

Below a link to a recently published overview of Oasmia Pharmaceuticals. As a fact document, we have no objections to the content, but would have preferred additional financial estimates, or at least a brief summary of the market potential - therefore, we ad our view below the link: http://microcapresearch.com/oasmia-pharmaceutical/ The market for cytotoxic agents within oncology is still, and for a number of years ahead, the basic medical treatment, where most new therapies are add-on’s. As many most ctotoxic agents (chemical compounds/small molecules), aren’t so specific on the cancerous cells, patients often suffer from serious side effects, sometimes disabelling optimal dosing. Still, chemo’s are considered as first line treatment in the vast majority of the patients. ...

Oasmia, has a vitamin-A based, nanotoech platform, named XR-17. The name XR-17, sounds like the name of a rocket or a missile - which is about to be launched! XR-17 platform, is defined as an excipient, which means it´s a mean to enhance administration and or distribution of a pharmaceutical compound - eg making established treatments better from a patient or clinical point of view. Paclitaxel, was the first compound to be re-developed within this technology - both as a treatment for canine cancer as well as for ovarian cancer in humans. ...